Navigation Links
RxElite Awarded Anesthetic Gases Multi-Source Contract by Premier Inc., a Purchasing Network for More than 1,500 U.S. Hospitals and 49,000 Other Healthcare Sites
Date:3/21/2008

MERIDIAN, Idaho, March 21 /PRNewswire-FirstCall/ -- RxElite, Inc. (OTC Bulletin Board: RXEI), a developer, manufacturer, and marketer of specialty generic prescription drug products, today announced the signing of a multi-source contract award with Premier, Inc. for the sale of RxElite's anesthetic gas products, Sevoflurane and Isoflurane. RxElite was awarded this multi-source contract listing for all classes of trade and the company's anesthetic gas products are immediately available to all Premier members. Sevoflurane is the most commonly used anesthetic gas in the United States and Isoflurane continues to be widely used in anesthesia practice.

"This contract has delivered significant value to the Premier members that have already implemented it and we look forward to continuing to drive value for all Premier members," stated Jonathan Houssian, CEO of RxElite.

RxElite anesthetic gases are manufactured by Minrad International, Inc., a leader in the innovation of anesthesia. RxElite holds the exclusive distribution rights for Minrad produced anesthetic gases for the human market in the United States.

About RxElite, Inc

RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia and sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs).

About Premier, Inc., 2006 Malcolm Baldrige National Quality Award recipient -- Serving 1,700 U.S. hospitals and more than 49,000 other healthcare sites, the Premier healthcare alliance and its members are transforming healthcare together. Owned by not-for-profit hospitals, Premier operates one of the leading healthcare purchasing networks and the nation's most comprehensive repository of hospital clinical and financial information. A subsidiary operates one of the nation's largest policy-holder owned, hospital professional liability risk-retention groups. A world leader in helping healthcare providers deliver dramatic improvements in care, Premier is working with the United Kingdom's National Health Service North West and the Centers for Medicare and Medicaid Services to improve hospital performance. Headquartered in San Diego, Premier has offices in Charlotte, N.C., Philadelphia, and Washington. For more information, visit http://www.premierinc.com . Established to improve the health of communities, Premier and its members are transforming healthcare together.

About Minrad International, Inc.

Minrad International, Inc. is an interventional pain management company with real-time image guidance and anesthesia and analgesia product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. Minrad International also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness. Additional information can be found at the company's website, http://www.minrad.com .

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

For More Information:

Corporate Information

Ph: (208) 288-5550

Toll Free: (800) 414-1901

Fax: (208) 288-1191

Investor Relations

Craig Bird, 215-885-4981

chbird@segue.biz

Segue Ventures LLC


'/>"/>
SOURCE RxElite, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. RxElite Files Registration Statement with Securities and Exchange Commission
2. RxElite Announces 3rd Quarter Financials Conference Call
3. RxElite Registration Statement Declared Effective by Securities and Exchange Commission
4. RxElite Registration Statement Suspended
5. RxElite Announces Acquisition of Assets of FineTech Laboratories
6. RxElite Inc. Fourth Quarter and Year-End 2007 Earnings Release and Conference Call Notice
7. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
8. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
9. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
10. PartsSource Awarded US Patent for PartsFinder(TM) Application
11. Wrigleys Orbit(R), Extra(R) and Eclipse(R) Sugar-Free Chewing Gums Awarded American Dental Associations Seal of Acceptance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
Breaking Medicine Technology: